Postings

Congress to protect all Medicare beneficiaries in reconciliation bill
Consumer Action joined 45 leading consumer, disability, minority health and provider organizations in thanking Congress for taking steps to protect Medicare Advantage beneficiaries when adding new benefits to fee-for-service (FFS) Medicare and encouraging lawmakers to maintain this language in the final bill. The letter comes as Congress considers adding vision, hearing and dental benefits to FFS Medicare as part of its emerging reconciliation package.

A call for President Biden to end Big Pharma monopolies
Coalition members wrote to U.S. Health and Human Services (HHS) Secretary Xavier Becerra demanding that the White House take on Big Pharma in an effort to curb drugmakers’ monopoly power in the soon-to-be-released HHS drug pricing competition plan. Advocates called on President Biden to end the era of abusive drug pricing and treatment rationing by challenging patents and expanding generic-drug competition. As Americans face a new surge in the ongoing pandemic, there is no better time than now to break up Big Pharma monopolies.

It’s time to dig deeper into sources of unfairness in auto insurance market
Consumer groups wrote to the Department of Treasury’s Federal Insurance Office (FIO) asking that the FIO prioritize an immediate update of its auto insurance affordability study using improved methods and conduct additional research on uninsured drivers, socioeconomic factors in auto insurance pricing, and how these factors have a disparate impact on people of color. As many families rely on automobiles to take them to school and work, it’s particularly important that auto insurance is available, affordable and priced fairly in the marketplace.

More can be done to protect consumers and patients during pharmaceutical mergers
The pharmaceutical industry has become increasingly concentrated in recent years, often resulting in higher prices and reduced choice for consumers. Increasing evidence shows that consumers are paying higher prices for prescription drugs and losing out on access and choice because of less innovation by drug companies. Advocates argue that the Federal Trade Commission’s current approach to monitoring pharmaceutical mergers, and its historically pro-merger policy, fails to fully protect American consumers and patients.

The FTC and CFPB must do more to prevent mass homelessness during the pandemic
Over 11 million families are at risk of losing housing. Protection from evictions and foreclosures is greatly needed due to the ongoing economic crisis accompanying the COVID-19 pandemic, including the loss of household income in the near and long term. Consumer Action joined advocates in urging the U.S. Federal Trade Commission and the Consumer Financial Protection Bureau to work together to prohibit unfair debt collections and ensure financial and regulatory agencies confirm industry standards regarding forbearance availability for homeowners. Without these additional protections, many will lose their homes and be forced to move at a time when COVID-19 levels are still extremely high and vaccination access for many is still months away. As a result, the financial impact of COVID would result in substantially greater risk of spreading illness.

Advocates urge the Biden administration to slash drug costs
Advocates wrote to the Biden administration asking the President-elect to immediately implement a series of reforms to slash prescription drug costs once he takes office. Advocates urged the President-elect to authorize more generic competition through patent licensing, launch a demonstration project in Medicare to link payments to vastly lower costs paid broadly and prosecute pharmaceutical companies for anti-competitive behavior. Americans currently spend more on prescription drugs than anyone else in the world. There were 717 drug price increases so far this year, and just seven of them on generics, bumping prices up by 4.5 percent on average. It’s time to improve the lives of patients and families by lowering drug prices and making medicines affordable.

Studies show systemic racism in insurance industry
Consumer Action joined a coalition of consumer and community activists in submitting comments to the National Association of Insurance Commissioners' Special Committee on Race and Insurance urging them to focus efforts on creating tools to help states and insurers identify and combat systemic racism in insurance. Studies over many years have shown elements of racism in pricing, placement of agents, redlining and other aspects of insurance. But systemic racism is not found in just a few elements of insurance; it casts its shadow across all aspects of insurance and needs to be confronted in a systematic and holistic manner.

Allies urge CFPB Director not to weaken its enforcement arm
A coalition of more than 80 consumer and civil rights groups urged the Consumer Financial Protection Bureau’s (CFPB) Director Kathy Kraninger to "abandon" her "October Surprise" proposed reorganization. Instead of strengthening the arm of the CFPB that holds predatory financial institutions accountable, the proposal would drastically weaken its authority, independence, and ultimately, effectiveness, leaving consumers vulnerable and defenseless during an already financially stressful time.

Seniors deserve a simplified Medicare enrollment process
Consumer Action joined Better Medicare Alliance (BMA), the leading research and advocacy organization supporting Medicare Advantage, in unveiling a new white paper that contains a set of comprehensive recommendations to reimagine Medicare enrollment and empower beneficiaries to make better sense of their coverage options. The coalition’s five-pronged plan, entitled “Empowering Beneficiaries and Modernizing Medicare Enrollment,” offers bold recommendations for reform, including shifting all Medicare enrollment responsibilities from the Social Security Administration to the Department of Health and Human Services.

Patients deserve access to cheaper prescription drugs
The Food and Drug Administration sought input for improvements to its generic drug approval process, including for complex generic drugs. Advocates stressed the importance of implementing policies that increase competition among drug companies and reduce barriers to cheaper prescription drugs. It’s time Americans have greater access to more affordable drugs and newly approved generic medicines.

Quick Menu

Facebook FTwitter T